Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations

Gelijkaardige items

• The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
  door: Hung, Ming-Szu, et al.
  Gepubliceerd in: (2016)
• Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
  door: Hung, Ming-Szu, et al.
  Gepubliceerd in: (2019)
• Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study
  door: Fang, Yu-Hung, et al.
  Gepubliceerd in: (2019)
• The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
  door: Wu, Shang-Gin, et al.
  Gepubliceerd in: (2016)
• Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
  door: Ming-Ju Tsai, et al.
  Gepubliceerd in: (2018-11-01)